secwatch.observer — SEC 8-K summary
======================================

Issuer:     Senti Biosciences, Inc. (SNTI)
CIK:        0001854270
Form:       8-K
Filed at:   2024-12-02T23:59:59+00:00
Accession:  0001140361-24-048114
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Senti Bio reports 2 of 3 AML patients achieve MRD-negative CR in Phase 1 SENTI-202 trial
--------------------------------------------------------------------------------

- Two of three R/R AML patients at lowest dose (1.0B CAR+ NK cells) achieved CR with MRD negativity; both maintain remission (4+ and 3+ months).
- SENTI-202 was generally well-tolerated with no DLTs; adverse events consistent with lymphodepleting chemotherapy and other investigational NK therapies.
- Dose escalation continues at 1.5B cells/dose level; additional safety, efficacy and durability data expected in 2025.
- SENTI-202 transgene detected in peripheral circulation of all patients across cycles, with PK profile similar to other CAR-NK therapies.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1854270/000114036124048114/0001140361-24-048114-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1854270/000114036124048114/ef20039399_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-24-048114

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer